In the current episode of “Immuno Oncology Talks”, we discuss the clinical challenges and future perspectives of CAR-T cells with our experts, from the Oslo University Hospital in Norway, Dr Else Marit Inderberg and Dr Sébastien Wälchli. Dr Inderberg is the head of the immunomonitoring at the hospital and has a research focus on novel immunotherapies, and Dr Wälchli is leading the CAR development platform. MAT-BE-2400334 (ver.1.0) 04 2024
All content for Immuno Oncology Talks is the property of Sanofi and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In the current episode of “Immuno Oncology Talks”, we discuss the clinical challenges and future perspectives of CAR-T cells with our experts, from the Oslo University Hospital in Norway, Dr Else Marit Inderberg and Dr Sébastien Wälchli. Dr Inderberg is the head of the immunomonitoring at the hospital and has a research focus on novel immunotherapies, and Dr Wälchli is leading the CAR development platform. MAT-BE-2400334 (ver.1.0) 04 2024
Cancer cell and gene therapies and the challenges to access the market
Immuno Oncology Talks
29 minutes
2 years ago
Cancer cell and gene therapies and the challenges to access the market
In our eight episode of the “Immuno Oncology Talks”, we will hear about the current challenges of getting cancer cell and gene therapies on the market from a health economic perspective. Our guest, Professor Cornelis Boersma, from University Medical Center Groningen and Open University, in the Netherlands, has an extensive experience within health economics and health care policy. Apart from his previous experience within the pharma industry, he is actively involved as a scientist, consultant...
Immuno Oncology Talks
In the current episode of “Immuno Oncology Talks”, we discuss the clinical challenges and future perspectives of CAR-T cells with our experts, from the Oslo University Hospital in Norway, Dr Else Marit Inderberg and Dr Sébastien Wälchli. Dr Inderberg is the head of the immunomonitoring at the hospital and has a research focus on novel immunotherapies, and Dr Wälchli is leading the CAR development platform. MAT-BE-2400334 (ver.1.0) 04 2024